Venatorx Pharmaceuticals
US-based Venatorx Pharmaceuticals develops solutions for multi-drug-resistant bacterial and tough viral infections.
Founded
2010US-based Venatorx Pharmaceuticals develops solutions for multi-drug-resistant bacterial and tough viral infections.
Founded in Malvern, United States, Venatorx Pharmaceuticals is a private company dedicated to discovering and developing novel anti-infectives aimed at treating multi-drug-resistant (MDR) bacterial infections and challenging viral infections. The company's core mission is to improve health outcomes for patients facing these severe health threats. Venatorx’s product pipeline includes innovative antibiotics and antiviral therapies designed to address the growing issue of drug resistance, which poses a significant public health risk globally.
Notable figures affiliated with Venatorx Pharmaceuticals include experienced scientists and industry leaders who contribute to its research and development efforts. The company has attracted investments from reputable venture capital firms, which underscores confidence in its mission and potential impact. Key achievements include successful preclinical and clinical trials that have demonstrated the efficacy of its drug candidates. Venatorx Pharmaceuticals has made a substantial impact by advancing treatments that could potentially save lives and curb the spread of resistant infections.
Companies similar to Venatorx Pharmaceuticals include Taxis Pharmaceuticals, Armata Pharmaceuticals, Revagenix and Enanta Pharmaceuticals.
Venatorx Pharmaceuticals was founded in 2010.
Venatorx Pharmaceuticals' headquarters is located in Malvern, PA, US.
Venatorx Pharmaceuticals' most recent funding round was for $24.7M (USD) in September 2022.
As of Sep 2, 2022, Venatorx Pharmaceuticals has raised a total of $165.7M (USD).
Venatorx Pharmaceuticals has 81 employees as of Feb 5, 2024.
Revagenix
revagenix.com
